# LRRK2 G2385R and R1628P Mutations Are Associated with an Increased Risk of Parkinson’s Disease in the Malaysian Population

Authors: Aroma Agape Gopalai; Shen-Yang Lim; Jing Yi Chua; Shelisa Tey; Thien Thien Lim; Norlinah Mohamed Ibrahim; Ai Huey Tan; Gaik Bee Eow; Zariah Abdul Aziz; Santhi Datuk Puvanarajah; Shanthi Viswanathan; Irene Looi; Soo Kun Lim; Li Ping Tan; Yip Boon Chong; Chong Tin Tan; Yi Zhao; E. K. Tan; Azlina Ahmad-Annuar
Journal: BioMed Research International
 (2014)

---

## Abstract

TheLRRK2 gene has been associated with both familial and sporadic forms of Parkinson’s disease (PD). The G2019S variant is commonly found in North African Arab and Caucasian PD patients, but this locus is monomorphic in Asians. The G2385R and R1628P variants are associated with a higher risk of developing PD in certain Asian populations but have not been studied in the Malaysian population. Therefore, we screened the G2385R and R1628P variants in 1,202 Malaysian subjects consisting of 695 cases and 507 controls. The G2385R and R1628P variants were associated with a 2.2-fold (P=0.019) and 1.2-fold (P=0.054) increased risk of PD, respectively. Our data concur with other reported findings in Chinese, Taiwanese, Singaporean, and Korean studies.


---

## Body

## 1. Introduction

Parkinson’s disease (PD) is an age-related illness, and, as populations age, the proportion of people with this neurodegenerative disease will continue to rise. It is projected that, by the year 2030, 9.3 million individuals above the age of 50 will suffer from PD and these cases will be concentrated outside the western world [1]. Studies have implicated exposure to environmental toxins and trauma as aetiological factors for PD [2]. Genetic variations also play a role, especially in cases where there is a family history of PD, which account for around 10–20% of all PD cases [3]. However, studies have shown that even late-onset sporadic PD may also have a genetic contribution [4].One of the genes commonly implicated in both familial and sporadic PD is the leucine-rich repeat kinase 2 (LRRK2) gene. Several variants ofLRRK2 such as R1441C, G2019S, and I2020T have been well established as risk factors for PD [3]. Interestingly, there appear to be population-specific variants in LRRK2; for example, the G2019S variant is prevalent among the Ashkenazi Jews and North African Arabs (occurring in approximately 20% and 40% of PD patients in these groups, respectively [5]) but is absent in Asian populations (Chinese, Indian, Korean, and Japanese) [6, 7]. In Asian (Chinese, Taiwanese, Singaporean, and Japanese) populations, the G2385R variant is a more established risk variant but conversely is not found in Caucasian or Jewish patients with PD [8–12]. The R1628P is another common risk variant in Asian PD populations (Chinese, Taiwanese, and Singaporean) [13].Given the lack of data regarding how these variants contribute to PD in Malaysian patients, we sought to investigate the prevalence of G2385R and R1628P in a Malaysian PD cohort. We found that G2385R was significantly associated with PD and R1628P showed a trend towards being a risk factor.


## 2. Methodology

A total of 1,202 subjects participated in this study. Six hundred and ninety-five PD patients were diagnosed by neurologists based on the United Kingdom PD Brain Bank Criteria and 507 controls who did not suffer from any neurological or movement disorders were recruited. Ethics approval and written consent from subjects were obtained. DNA was extracted from lymphocytes that were obtained from venous blood using the phenol-chloroform method. The G2385R (rs34778348) and R1628P (rs33949390) genotyping was done by Taqman allelic discrimination assay on a 7500 Fast Real-Time PCR machine. A subset of 20 individuals was sequenced to determine the error rate. The allele and genotype frequencies in PD cases and controls were compared with Fisher’s exact test. Statistical analyses were performed using an open-source software (OpenEpi).


## 3. Results and Discussion

The mean age at PD diagnosis was57.4±11.8 years and the mean age of controls was 59.3±9.4 years. Sixty percent of PD patients and 51% of controls were male. Results of the G2385R and R1628P genotyping are summarised in Table 1. The error rate of the assay was 0% in the subset of 20 individuals. Fifty-five patients (7.9%) had early-onset PD (onset < 40 years). Four patients were compound heterozygous for G2385R and R1628P; two of these patients had a family history of PD and developed PD before the age of 50, while the other two patients had no family history and had a later age of onset (>55).Table 1
Summary of the genotyping data.
SNP
PD (MAF)
Controls (MAF)
OR (95% confidence interval)
G2385R (c.7153G>A), rs34778348
Wild type (G)
1354 (0.974)
1002 (0.999)
OR 2.22 (1.15–4.29)
Variant (A)
36 (0.026)
12 (0.001)
P
=
0.019
R1628P (c.4883G>C), rs33949390
Wild type (G)
1347 (0.969)
996 (0.982)
OR 1.23 (1.039–1.448)
Variant (C)
43 (0.031)
18 (0.018)
P
=
0.054The G2385R variant was associated with PD, with an odds ratio (OR) of 2.22 (P=0.019), while the R1628P variant had an OR of 1.23 with a trend towards significance (P=0.054). Interestingly, the G2385R mutation was present in control subjects as well (MAF = 0.001), although it was less frequently present than in the PD cohort (MAF = 0.026).Our findings are in keeping with other published reports on G2385R, where this variant is associated with an increased risk of developing PD by approximately twofold (Chinese, Taiwanese, Singaporean, and Japanese populations) (Table2). The G2385R variant is located within the WD40 domain ofLRRK2, which is responsible for a variety of functions including signal transduction, pre-mRNA processing, and cytoskeleton assembly, and cells carrying the G2385R variant are more susceptible to oxidative stress and apoptosis [14].Table 2
Summary of published Asian data on G2385R and R1628P.
Study
Asian country
Sample size
Results
G2385R (c.7153G>A), rs34778348
Di Fonzo et al., 2006 [9]
Taiwan
608 PD, 373 controls
OR 2.24(P=0.004)
Fung etal., 2006 [20]
Taiwan
305 PD, 176 controls
OR 17.00(P=0.0002)
Farrer et al., 2007 [21]
Taiwan
410 PD, 335 controls
OR 2.24(P=0.014)
Tan et al., 2007 [14]
Singapore
495 PD, 494 controls
OR 2.14(P=0.014)
Tan et al., 2007 [16]
Non-Chinese Asian (Malays and Indians)
98 PD, 173 controls66 PD, 133 controls
MalaysOR 1.78 (P=0.3) Indians-monomorphic
An et al., 2008 [11]
Mainland China
600 PD, 334 controls
OR 3.94(P<0.01)
Funayama et al., 2007 [10]
Japan
448 PD, 457 controls
OR 2.60(P=1.24×10-4)
Zabetian et al., 2009 [7]
Japan
601 PD, 1,628 controls
OR 1.96(P<0.001)
Miyake et al., 2010 [22]
Japan
229 PD, 358 controls
OR 2.06
Kim et al., 2010 [12]
Korea
923 PD, 422 controls119 YOPD814 LOPD
CombinedOR 1.83 (P=0.017) YOPD OR 2.28 (P=0.098) LOPD OR 1.81 (P=0.022)
Ross et al., 2011 [19]
Asian
Taiwanese369 PD, 300 controlsKorean844 PD, 587 controlsJapanese173 PD, 95 controlsCombined1,386 PD, 982 controls
OR 1.62*P value not statedOR 1.87 *P value not statedOR 1.44 *P value not statedOR 1.73 (P=0.0026)
Current study
Malaysia
695 PD, 507 controls
OR 2.22(P=0.019)
R1628P(c.4883G>C), rs33949390
Mata et al., 2005 [15]
Europe, Asia, and North America
100 PD probands with family history of parkinsonism,300 controls
MAF 0.01
Lu et al., 2008 [18]
Taiwan
834 PD, 543 controls
OR 2.13(P=0.004)
Tan et al., 2008 [16]
Singapore
246 PD, 243 controls
OR 2.5(P=0.046)
Tan et al., 2008 [23]
Non-Chinese Asian (Malays and Indians)
132 PD, 160 controls60 PD, 105 controls
OR 0.61(P=0.600) Indians-monomorphic
Ross et al., 2008 [13]
Taiwan, Singapore
Wu RM484 PD, 341 controlsWu YR345 PD, 316 controlsEK Tan250 PD, 250 controlsCombined1079 PD, 907 controls
OR 2.15(P=0.025) OR 1.39 (P=0.179) OR 2.20 (P=0.163) OR 1.84 (P=0.006)
Zabetian et al., 2009 [7]
Japanese
631 PD, 320 controls
Monomorphic
Yu et al., 2009 [24]
Mainland China
328 PD, 300 controls
OR 2.68(P<0.05)
Zhang et al., 2009 [25]
Mainland China
600 PD, 459 controls
OR 3.14(P<0.01)
Kim et al., 2010 [12]
Korea
384 PD, 384 controls
OR 2.98(P=0.32)
Pulkes et al., 2011 [17]
Thai
154 PD, 156 controls
OR 3.25(P=0.021)
Ross et al., 2011 [19]
Asian
Taiwanese(369 PD, 300 controls)
OR 0.56(P=0.054)
Korean(844 PD, 587 controls)
OR 2.47(P=0.42)
Japanese(173 PD, 95 controls)
Monomorphic
Combined(1,386 PD, 982 controls)
OR 0.62(P=0.087)
Current study
Malaysian
695 PD, 507 controls
OR 1.23(P=0.054)The R1628P variant was first identified by Mata et al. [15]. Subsequently, Ross et al. reported this variant to be the second common genetic risk factor for PD in the ethnic Chinese (Taiwanese and Singaporean) population, with an OR of 1.84 (P=0.006) [13]. Other independent studies carried out by Tan et al., Pulkes et al., and Lu et al. in Singapore, Thailand, and China showed a similar trend with OR values of 2.5, 3.3, and 2.1, respectively [16–18]. However, this was not observed in a Japanese cohort where the locus was found to be monomorphic [7]. This mutation alters a highly conserved amino residue within the “COR” domain of the LRRK2 protein [18]. The substitution of a highly basic polar arginine (R) with a neutral nonpolar proline (P) is likely to cause a conformational change in the protein secondary structure, thus altering the function of the protein. We note however that a recent multicentre study by Ross et al. involving 1386 Asian PD cases and 982 Asian controls did not find an association with R1628P (OR 0.62, 95% CI 0.36–1.07, P=0.087) [19]. Whilst the findings in their Japanese and Korean subsets were consistent with previously published data, their Taiwanese cohort did not show a risk association, but rather a trend in the opposite direction (i.e., protective, with an OR of 0.56, 95% CI 0.32–1.01, P=0.054).In conclusion, our data concur with other reports in the Chinese, Taiwanese, Singaporean, and Korean populations. The G2385R variant is significantly associated with an increased risk of developing PD, while the R1628P variant is predicted to have a more modest effect. These data together with others can lead to a better understanding of the pathogenetic pathways leading to cell dysfunction and death in PD, with the ultimate hope that more specific drugs can be developed to treat this disabling disease.



---

*Source: 867321-2014-08-28.xml*